Novartis AG (NOVN) Given a CHF 90 Price Target by HSBC Holdings plc Analysts

Novartis AG (VTX:NOVN) has been given a CHF 90 price objective by analysts at HSBC Holdings plc in a research report issued to clients and investors on Tuesday. The firm presently has a “buy” rating on the stock.

Several other brokerages have also weighed in on NOVN. Deutsche Bank AG set a CHF 80 price objective on shares of Novartis AG and gave the company a “neutral” rating in a research report on Friday, July 7th. Credit Suisse Group set a CHF 77 price objective on shares of Novartis AG and gave the company a “sell” rating in a research report on Wednesday, July 5th. Kepler Capital Markets set a CHF 88 price objective on shares of Novartis AG and gave the company a “buy” rating in a research report on Tuesday, July 4th. Jefferies Group LLC set a CHF 103 price objective on shares of Novartis AG and gave the company a “buy” rating in a research report on Friday, June 23rd. Finally, Barclays PLC set a CHF 80 price objective on shares of Novartis AG and gave the company a “neutral” rating in a research report on Friday, June 23rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of CHF 85.

Novartis AG (VTX:NOVN) opened at 82.90 on Tuesday. Novartis AG has a 52-week low of CHK 67.40 and a 52-week high of CHK 84.35. The stock’s 50 day moving average price is CHK 81.20 and its 200 day moving average price is CHK 78.64. The firm has a market capitalization of CHK 194.23 billion and a price-to-earnings ratio of 30.27.

COPYRIGHT VIOLATION NOTICE: “Novartis AG (NOVN) Given a CHF 90 Price Target by HSBC Holdings plc Analysts” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/21/novartis-ag-novn-given-a-chf-90-price-target-by-hsbc-holdings-plc-analysts.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply